Schrödinger, Inc.
NASDAQ:SDGRMedical - Healthcare Information Services
+$0.00 today
- Market cap
- $1.79B
- Beta
- 1.64
- P/E (TTM)
- -11.1
- EPS (TTM)
- -$1.40
Volume 1.18M
Average 1.35M
SDGR Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Schrödinger, Inc.NASDAQ: SDGR
Accounts Receivables · Q3 FY2026 · quarter ended Sep 2026
Accounts receivables growth accelerates
Q3 FY2026 accounts receivables of $26.97M (cash outflow) rose 30.8% year over year, ahead of the -2.1% change in trailing-twelve-month accounts receivables.
Context
- Accounts receivables amounted to 59.0% of revenue in FY2025, down 21.1 pp from a year earlier.
- Accounts receivables increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +30.8% holds above the trailing-twelve-month pace of -2.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- 150.94M USD
- Year-over-year change
- +190.8%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 150.94M | +190.8% |
| FY2024 | 2024-12-31 | (166.22M) | -730.0% |
| FY2023 | 2023-12-31 | (20.03M) | +28.4% |
| FY2022 | 2022-12-31 | (27.95M) | -407.4% |
| FY2021 | 2021-12-31 | (5.51M) | — |
Accounts Receivables vs competitors
How SDGR compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -2.1% is the 5th highest of 7, against a peer median of +22.7%.
- Accounts receivables amounts to 4.6% of revenue for SDGR, versus a peer median of 2.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $88.04M USD | +26.4% | +40.9% | 2.5% | |
| LTM Sep 2026 | $43.84M USD | +19.1% | +34.8% | 64.6% | |
| LTM Sep 2026 | $12.31M USD | -2.1% | — | 4.6% | |
HYFTMindWalk Holdings Corp. | LTM Jan 2026 | CA$2.09M CAD | -445.0% | — | 11.4% |
| LTM Feb 2026 | $1.68M USD | +27.5% | -47.2% | 2.1% | |
| LTM Mar 2026 | $1.41M USD | -87.3% | — | 0.3% | |
GENBGenerate Biomedicines, Inc. | FY2025 | $308K USD | +244.6% | — | 1.0% |
| LTM Jun 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | — | |
| Peer median (excluding SDGR) | — | +22.7% | +34.8% | 2.1% | |
Competitors are the stored peer set for SDGR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (101.22M) | (149.19M) | 40.72M | (187.12M) | (103.27M) |
| Depreciation & Amortization | 2.85M | 4.34M | 5.55M | 6.16M | 6.02M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 26.49M | 39.63M | 47.84M | 49.9M | 43M |
| Change in Working Capital | 4.68M | (21.38M) | (22.55M) | (13.04M) | 118.17M |
| Accounts Receivables | (5.51M) | (27.95M) | (20.03M) | (166.22M) | 150.94M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (411K) | 1.18M | 7.32M | (6.12M) | 908K |
| Other Working Capital | 10.6M | 5.39M | (9.85M) | 159.3M | (33.68M) |
| Other Non-Cash Items | (3.46M) | 6.91M | (208.29M) | (13.27M) | (50.02M) |
| Operating Cash Flow | (70.67M) | (119.68M) | (136.73M) | (157.37M) | 13.9M |
| Capital Expenditures | (7.17M) | (8.01M) | (13.4M) | (7.31M) | (1.44M) |
| Acquisitions (Net) | 0 | (7.03M) | (4.13M) | 45.73M | 0 |
| Purchases of Investments | (418.5M) | (271.47M) | (320.62M) | (251.34M) | (312.96M) |
| Sales of Investments | 408.48M | 364.71M | 383.97M | 361.76M | 372.3M |
| Other Investing Activities | 375K | 11.83M | 147.21M | 0 | 0 |
| Investing Cash Flow | (16.81M) | 90.02M | 193.03M | 148.84M | 57.9M |
| Debt Repayment | 0 | 0 | (19K) | (58K) | (58K) |
| Common Stock Issued | 0 | 0 | 0 | 8.87M | 2.99M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 7.95M | 2.11M | 9.07M | 1.31M | 0 |
| Financing Cash Flow | 7.95M | 2.11M | 9.05M | 10.12M | 2.93M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (79.53M) | (27.55M) | 65.35M | 1.59M | 74.73M |
| Free Cash Flow | (77.84M) | (127.7M) | (150.14M) | (164.68M) | 12.46M |
Schrödinger, Inc.
NASDAQ:SDGR
Intrinsic Alpha fair value
Locked
Current Price
$27.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.